vs
Amphastar Pharmaceuticals, Inc.（AMPH）与史密斯威森（SWBI）财务数据对比。点击上方公司名可切换其他公司
Amphastar Pharmaceuticals, Inc.的季度营收约是史密斯威森的1.5倍（$183.1M vs $124.7M），Amphastar Pharmaceuticals, Inc.净利率更高（13.3% vs 1.5%，领先11.8%），Amphastar Pharmaceuticals, Inc.同比增速更快（-1.8% vs -3.9%），Amphastar Pharmaceuticals, Inc.自由现金流更多（$24.6M vs $16.3M），过去两年Amphastar Pharmaceuticals, Inc.的营收复合增速更高（3.2% vs -4.8%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
史密斯韦森品牌公司是总部位于美国田纳西州玛丽维尔的美国枪械制造商，是美国历史悠久的知名枪械生产企业，在民用和执法枪械领域拥有较高的市场知名度。
AMPH vs SWBI — 直观对比
营收规模更大
AMPH
是对方的1.5倍
$124.7M
营收增速更快
AMPH
高出2.0%
-3.9%
净利率更高
AMPH
高出11.8%
1.5%
自由现金流更多
AMPH
多$8.3M
$16.3M
两年增速更快
AMPH
近两年复合增速
-4.8%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $124.7M |
| 净利润 | $24.4M | $1.9M |
| 毛利率 | 46.8% | 24.3% |
| 营业利润率 | 19.4% | 3.3% |
| 净利率 | 13.3% | 1.5% |
| 营收同比 | -1.8% | -3.9% |
| 净利润同比 | -35.7% | -53.6% |
| 每股收益（稀释后） | $0.51 | $0.04 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHSWBI
| Q4 25 | $183.1M | $124.7M | ||
| Q3 25 | $191.8M | $85.1M | ||
| Q2 25 | $174.4M | $140.8M | ||
| Q1 25 | $170.5M | $115.9M | ||
| Q4 24 | $186.5M | $129.7M | ||
| Q3 24 | $191.2M | $88.3M | ||
| Q2 24 | $182.4M | $159.1M | ||
| Q1 24 | $171.8M | $137.5M |
净利润AMPHSWBI
| Q4 25 | $24.4M | $1.9M | ||
| Q3 25 | $17.4M | $-3.4M | ||
| Q2 25 | $31.0M | $8.6M | ||
| Q1 25 | $25.3M | $2.1M | ||
| Q4 24 | $38.0M | $4.5M | ||
| Q3 24 | $40.4M | $-1.9M | ||
| Q2 24 | $37.9M | $27.9M | ||
| Q1 24 | $43.2M | $7.9M |
毛利率AMPHSWBI
| Q4 25 | 46.8% | 24.3% | ||
| Q3 25 | 51.4% | 25.9% | ||
| Q2 25 | 49.6% | 28.8% | ||
| Q1 25 | 50.0% | 24.1% | ||
| Q4 24 | 46.5% | 26.6% | ||
| Q3 24 | 53.3% | 27.4% | ||
| Q2 24 | 52.2% | 35.5% | ||
| Q1 24 | 52.4% | 28.7% |
营业利润率AMPHSWBI
| Q4 25 | 19.4% | 3.3% | ||
| Q3 25 | 13.2% | -3.5% | ||
| Q2 25 | 24.2% | 9.3% | ||
| Q1 25 | 21.9% | 4.1% | ||
| Q4 24 | 24.2% | 5.8% | ||
| Q3 24 | 29.8% | -1.7% | ||
| Q2 24 | 30.3% | 17.4% | ||
| Q1 24 | 27.9% | 8.2% |
净利率AMPHSWBI
| Q4 25 | 13.3% | 1.5% | ||
| Q3 25 | 9.0% | -4.0% | ||
| Q2 25 | 17.8% | 6.1% | ||
| Q1 25 | 14.8% | 1.8% | ||
| Q4 24 | 20.4% | 3.5% | ||
| Q3 24 | 21.1% | -2.1% | ||
| Q2 24 | 20.8% | 17.5% | ||
| Q1 24 | 25.1% | 5.7% |
每股收益（稀释后）AMPHSWBI
| Q4 25 | $0.51 | $0.04 | ||
| Q3 25 | $0.37 | $-0.08 | ||
| Q2 25 | $0.64 | $0.19 | ||
| Q1 25 | $0.51 | $0.05 | ||
| Q4 24 | $0.74 | $0.10 | ||
| Q3 24 | $0.78 | $-0.04 | ||
| Q2 24 | $0.73 | $0.60 | ||
| Q1 24 | $0.81 | $0.17 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | $22.4M |
| 总债务越低越好 | $608.7M | — |
| 股东权益账面价值 | $788.8M | $363.2M |
| 总资产 | $1.6B | $548.6M |
| 负债/权益比越低杠杆越低 | 0.77× | — |
8季度趋势，按日历期对齐
现金及短期投资AMPHSWBI
| Q4 25 | $282.8M | $22.4M | ||
| Q3 25 | $276.2M | $18.0M | ||
| Q2 25 | $231.8M | $25.2M | ||
| Q1 25 | $236.9M | $26.7M | ||
| Q4 24 | $221.6M | $39.1M | ||
| Q3 24 | $250.5M | $35.5M | ||
| Q2 24 | $217.8M | $60.8M | ||
| Q1 24 | $289.6M | $47.4M |
总债务AMPHSWBI
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
股东权益AMPHSWBI
| Q4 25 | $788.8M | $363.2M | ||
| Q3 25 | $776.7M | $364.4M | ||
| Q2 25 | $757.5M | $372.5M | ||
| Q1 25 | $751.3M | $366.9M | ||
| Q4 24 | $732.3M | $371.5M | ||
| Q3 24 | $727.7M | $380.0M | ||
| Q2 24 | $713.3M | $399.9M | ||
| Q1 24 | $672.4M | $376.4M |
总资产AMPHSWBI
| Q4 25 | $1.6B | $548.6M | ||
| Q3 25 | $1.7B | $554.6M | ||
| Q2 25 | $1.6B | $559.6M | ||
| Q1 25 | $1.6B | $578.9M | ||
| Q4 24 | $1.6B | $587.4M | ||
| Q3 24 | $1.5B | $571.3M | ||
| Q2 24 | $1.5B | $577.4M | ||
| Q1 24 | $1.6B | $570.6M |
负债/权益比AMPHSWBI
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | $27.3M |
| 自由现金流经营现金流 - 资本支出 | $24.6M | $16.3M |
| 自由现金流率自由现金流/营收 | 13.4% | 13.1% |
| 资本支出强度资本支出/营收 | 4.5% | 8.8% |
| 现金转化率经营现金流/净利润 | 1.35× | 14.22× |
| 过去12个月自由现金流最近4个季度 | $121.2M | $21.3M |
8季度趋势，按日历期对齐
经营现金流AMPHSWBI
| Q4 25 | $32.9M | $27.3M | ||
| Q3 25 | $52.6M | $-8.1M | ||
| Q2 25 | $35.6M | $40.8M | ||
| Q1 25 | $35.1M | $-9.8M | ||
| Q4 24 | $29.0M | $-7.4M | ||
| Q3 24 | $60.0M | $-30.8M | ||
| Q2 24 | $69.1M | $43.7M | ||
| Q1 24 | $55.3M | $25.2M |
自由现金流AMPHSWBI
| Q4 25 | $24.6M | $16.3M | ||
| Q3 25 | $47.2M | $-12.4M | ||
| Q2 25 | $25.0M | $33.5M | ||
| Q1 25 | $24.4M | $-16.1M | ||
| Q4 24 | $16.6M | $-10.7M | ||
| Q3 24 | $46.2M | $-35.5M | ||
| Q2 24 | $63.1M | $38.2M | ||
| Q1 24 | $46.5M | $7.0M |
自由现金流率AMPHSWBI
| Q4 25 | 13.4% | 13.1% | ||
| Q3 25 | 24.6% | -14.6% | ||
| Q2 25 | 14.3% | 23.8% | ||
| Q1 25 | 14.3% | -13.9% | ||
| Q4 24 | 8.9% | -8.3% | ||
| Q3 24 | 24.1% | -40.2% | ||
| Q2 24 | 34.6% | 24.0% | ||
| Q1 24 | 27.1% | 5.1% |
资本支出强度AMPHSWBI
| Q4 25 | 4.5% | 8.8% | ||
| Q3 25 | 2.8% | 5.0% | ||
| Q2 25 | 6.1% | 5.2% | ||
| Q1 25 | 6.3% | 5.4% | ||
| Q4 24 | 6.7% | 2.5% | ||
| Q3 24 | 7.2% | 5.3% | ||
| Q2 24 | 3.3% | 3.5% | ||
| Q1 24 | 5.1% | 13.2% |
现金转化率AMPHSWBI
| Q4 25 | 1.35× | 14.22× | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | 4.73× | ||
| Q1 25 | 1.39× | -4.68× | ||
| Q4 24 | 0.76× | -1.63× | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | 1.57× | ||
| Q1 24 | 1.28× | 3.20× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
SWBI
暂无分部数据
